Currently out of the existing stock ratings of Matthew Barcus, 30 are a BUY (90.91%), 3 are a HOLD (9.09%).

Matthew Barcus

Work Performance Price Targets & Ratings Chart

Analyst Matthew Barcus, currently employed carries an average stock price target met ratio of 36.67% that have a potential upside of 65.1% achieved within 160 days. Previously, Matthew Barcus worked at CHARDAN CAPITAL.

Matthew Barcus’s has documented 61 price targets and ratings displayed on 10 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on QURE, Uniqure NV at 22-Jun-2023.

Wall Street Analyst Matthew Barcus

Analyst best performing recommendations are on IMVT (IMMUNOVANT ).
The best stock recommendation documented was for IMVT (IMMUNOVANT ) at 9/29/2022. The price target of $12 was fulfilled within 36 days with a profit of $6.62 (123.05%) receiving and performance score of 34.18.

Average potential price target upside

of $6.89 (77.95%) on IMVT (IMMUNOVANT ).
of $6.51 (177.24%) on IMNM (IMMUNOME ).
of $2.12 (189.03%) on VINC (VINCERX PHARMA).

IMNM Immunome IMVT Immunovant VBLT Vascular Biogenics Ltd VINC Vincerx Pharma FIXX Homology Medicines ONCR Oncorus AMTI Applied Molecular Transport ANIX Anixa Biosciences QURE Uniqure NV XLO Xilio Development

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

David Nierengarten (WEDBUSH)